Digest Network Come funziona
Network
/
Società
Ro
Non verificato

Rona Therapeutics

Di cosa scriviamo

BiologiaFarmaceuticaFinanzaSanitàScienza

5 comunicati stampa

Guarda tutti i comunicati
29/05/2025
Farmaceutica
Sanità
Scienza
Biologia
Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025
Fonte
Rona Therapeutics
Emittente
PR News Wire
1.00
0
21/04/2025
Farmaceutica
Sanità
Biologia
Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Fonte
Rona Therapeutics
Emittente
PR News Wire
1.00
0
17/03/2025
Farmaceutica
Sanità
Biologia
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
Fonte
Rona Therapeutics
Emittente
PR News Wire
1.00
0
18/11/2024
Farmaceutica
Sanità
Finanza
Scienza
Biologia
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions
Fonte
Rona Therapeutics
Emittente
PR News Wire
1.00
0
19/07/2024
Farmaceutica
Sanità
Finanza
Banca
Mutui
Risparmio/Affari personali
Leasing
Gestione dei titoli obbligazionari
Fondi di investimento
Euro-obbligazioni
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Fonte
Rona Therapeutics
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0